Selank — Tuftsin-Derivative Anxiolytic Heptapeptide

Discovery and Origin

Selank was developed in the late nineteen-eighties by researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences, led in part by the laboratory of Marina Kozlovskaya. The conceptual starting point was tuftsin, a naturally occurring immunopeptide tetrapeptide (Thr-Lys-Pro-Arg) cleaved from the Fc region of IgG immunoglobulin. Tuftsin had long been known to stimulate macrophage activity and exhibit modest anxiolytic properties in rodent models, but its extremely short half-life — measured in seconds in plasma due to rapid leucine aminopeptidase and carboxypeptidase cleavage — rendered it pharmacologically impractical.

The Russian Academy team addressed this limitation using the same design principle that had yielded Semax: appending a stabilising C-terminal extension. The addition of Pro-Gly-Pro to the tuftsin core produced the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, registered under the name Selank (also designated TP-seven in the experimental literature). The tripeptide tail substantially extended the metabolic lifetime of the molecule without altering its fundamental pharmacological character [PMID:22662104]. Unlike tuftsin, which exerts primarily peripheral immunological actions, Selank was designed from the outset to penetrate the central nervous system via intranasal delivery, a route that exploits olfactory and trigeminal nerve pathways to bypass the blood-brain barrier.

By the late nineteen-nineties, Selank had moved through preclinical toxicology and into controlled human trials within Russia. The Russian Ministry of Health approved it as an anxiolytic medicinal product — sold commercially under the trade name Selank — and it occupies an unusual regulatory niche as one of very few peptide anxiolytics with formal governmental approval anywhere in the world. Its approval was driven primarily by data from Phase II and Phase III trials conducted at the Serbsky National Medical Research Centre for Psychiatry and the Bekhterev Psychoneurological Research Institute, which documented anxiolytic efficacy comparable to fenazepam (a Soviet-era benzodiazepine) without the dependence and sedation profile associated with that drug class.

Mechanism of Action

Selank's pharmacology does not map neatly onto any single receptor class, which partly explains why it resisted straightforward characterisation for many years. Its anxiolytic activity is mediated through several converging pathways rather than one dominant molecular target.

GABAergic Modulation Without Benzodiazepine Site Binding. Selank enhances GABAergic neurotransmission and produces electrophysiological and behavioural profiles consistent with positive allosteric GABA-A modulation. Critically, receptor binding studies have demonstrated that it does not compete for the benzodiazepine binding site on the GABA-A receptor complex [PMID:22662104]. This distinction is pharmacologically important: benzodiazepines produce dependence and receptor downregulation in part through their specific allosteric site; Selank's GABAergic enhancement appears to proceed through a different modulatory mechanism, which would account for the absence of tolerance and withdrawal observed in published animal and human studies.

Enkephalin Metabolism. Semenova and colleagues demonstrated that Selank influences the activity of enkephalin-degrading enzymes, effectively slowing the catabolism of endogenous met-enkephalin and leu-enkephalin in brain tissue [PMID:11830764]. Elevated central enkephalin tone contributes to anxiolysis, analgesia, and mood stabilisation through mu and delta opioid receptor activation. This mechanism is distinct from exogenous opioid agonism — Selank does not bind opioid receptors directly but preserves the half-life of the brain's own enkephalins.

Serotonergic Enhancement. Semenova's work also identified a modulatory effect on serotonin turnover, with Selank increasing extracellular serotonin availability in limbic regions relevant to anxiety regulation, including the amygdala and hippocampus [PMID:11830764]. This serotonergic component may explain the reported improvements in mood stability and emotional resilience that subjects report extending beyond the acute anxiolytic effect.

BDNF Upregulation. Kolomin and colleagues, using transcriptomic approaches similar to those applied to Semax, identified that Selank upregulates brain-derived neurotrophic factor expression in cortical and hippocampal tissue following repeated administration [PMID:22072002]. BDNF upregulation is associated with synaptic plasticity, memory consolidation, and resilience to stress-induced neuronal remodelling — providing a mechanistic basis for the nootropic and stress-protective properties attributed to Selank beyond its acute anxiolytic profile.

Immunomodulatory Activity. Reflecting its tuftsin heritage, Selank retains meaningful immunomodulatory activity. Vyunova and colleagues documented changes in cytokine profiles — including modulation of interleukin-six and tumour necrosis factor-alpha — following Selank administration, suggesting that the peptide has anti-inflammatory CNS effects in addition to its neurotransmitter-level actions [PMID:22662104].

Researched Applications

Generalised Anxiety and Adjustment Disorders. The most extensively documented clinical application is the treatment of generalised anxiety disorder and anxiety associated with adjustment disorders. Russian Phase II and Phase III trials comparing Selank to the benzodiazepine fenazepam and to placebo found that Selank produced anxiolytic effects of similar magnitude to fenazepam on validated rating scales (Hamilton Anxiety Rating Scale) while producing significantly less sedation and no measurable physiological dependence at protocol end [PMID:22662104]. Onset of effect was observed within the first week of treatment in the majority of subjects.

Post-Traumatic Stress Models. Sudakov and colleagues used a learned-helplessness rodent model — a well-validated preclinical proxy for post-traumatic stress disorder — to evaluate Selank's effects on conditioned fear and stress reactivity. Selank-treated animals displayed significantly attenuated passive avoidance deficit and reduced corticosterone response to repeated stressors compared to controls [PMID:15378174]. These findings have generated interest in Selank as a potential adjunct in PTSD research protocols, though human clinical data for this indication remains limited to preliminary observational work.

Cognitive Enhancement and ADHD. Because Selank's anxiolytic effect is not accompanied by sedation or cognitive impairment — which benzodiazepines typically produce — and because of its BDNF-upregulating and serotonergic properties, researchers have investigated its potential as a cognitive adjunct. Russian open-label data and self-report surveys suggest improvements in working memory, learning speed, and attentional focus. Preliminary work in rodent models of attention deficit suggests dopaminergic-adjacent effects that may be relevant to attention-deficit disorder; no controlled human trials exist for this indication outside the Russian federation.

Immunological Stress Response. Given Selank's tuftsin lineage, a line of research has examined whether it modulates immune function during psychological stress — a clinically relevant question because chronic anxiety disorders are associated with elevated inflammatory markers. Cytokine data from Vyunova suggest normalisation of stress-elevated interleukin profiles, though this research remains at an early stage.

Dosing Protocols (Research Context)

The dose range documented in Russian clinical trials and consistently referenced in contemporary research practice is four hundred to eight hundred micrograms per day, administered intranasally and divided across two sessions. A representative protocol would be:

• Morning: two hundred to four hundred micrograms intranasal (one to two drops of a standard 0.15% solution per nostril)
• Evening: two hundred to four hundred micrograms intranasal

The standard commercial Russian formulation is a 0.15% intranasal solution (one and a half milligrams per millilitre), with each drop from a standard dropper delivering approximately seventy-five micrograms per nostril. Researchers working with a 0.1% formulation adjust drop count accordingly. The lower end of the range (four hundred micrograms per day) is typically sufficient for anxiolytic effect; the upper end may be used when the nootropic or immunomodulatory profile is the primary research interest.

Cycle length in published Russian clinical protocols is ten to fourteen days. No rebound anxiety or withdrawal phenomenon has been observed at end of treatment, and longer cycles of three to four weeks are used in some observational settings without reported consequence. Subcutaneous administration at equivalent microgram doses is used in research contexts but is not the validated clinical route; intranasal delivery is preferred for CNS targeting.

Safety Profile

Selank has an unusually well-characterised safety record for a peptide compound operating outside Western regulatory frameworks, attributable to three decades of regulated human use in Russia. The adverse effect profile documented in clinical trials is minimal.

The most frequently reported side effect is mild transient nasal irritation — rhinorrhoea, brief burning, or mild congestion — on administration, which typically resolves within minutes. This is consistent with the intranasal route and appears to diminish with repeated exposure as the nasal mucosa adapts.

No dependence liability has been identified in controlled studies. Unlike benzodiazepines, Selank does not produce the receptor downregulation that drives physiological tolerance and withdrawal. No craving, rebound anxiety, or withdrawal syndrome has been documented in subjects completing ten to fourteen day protocols in clinical trials. Animal studies using extended-duration dosing did not reveal any of the behavioural correlates of dependence [PMID:22662104].

At doses substantially above the clinical range in rodent studies, no organ toxicity was identified. Selank undergoes rapid proteolytic breakdown to its constituent amino acids and does not bioaccumulate. It does not measurably alter cortisol, gonadal hormone, thyroid hormone, or pituitary axis activity at research-relevant doses. The peptide does not appear to interact with common medications, though no formal drug-drug interaction studies exist in humans. Individuals with severe allergic rhinitis should exercise caution with the intranasal route.

UK Regulatory Status

Selank is not a licensed medicinal product in the United Kingdom and has not been evaluated by the Medicines and Healthcare products Regulatory Agency for human use. It is not listed as a controlled substance under the Misuse of Drugs Act 1971 and does not clearly meet the definition of a psychoactive substance under the Psychoactive Substances Act 2016 in its current scheduling guidance, placing it in a legal grey zone rather than explicit prohibition.

However, Selank is an unlicensed medicinal product and its supply or clinical administration by healthcare professionals would fall under MHRA jurisdiction and require a Specials licence or equivalent authorisation. Importation for personal research use is not explicitly criminalised but carries regulatory risk; MHRA border agencies do intercept unlicensed peptide products, and any risk associated with importation rests entirely with the individual. Researchers should consult current MHRA import guidance and seek independent legal advice before proceeding.

Reconstitution and Administration

The most widely available commercial preparation of Selank is a pre-dissolved intranasal solution at 0.15% concentration supplied in a multi-dose vial. This matches the formulation used in Russian clinical trials and is the standard against which dosing guidance is calibrated. Each drop from a standard dropper delivers approximately seventy-five micrograms, allowing straightforward dose titration. Vials should be stored refrigerated at two to eight degrees Celsius and used within thirty days of opening; the solution does not require preservatives for stability within this period if kept cold and handled aseptically.

Researchers working with lyophilised Selank powder should reconstitute in sterile bacteriostatic water to achieve a 0.15% concentration (one and a half milligrams per millilitre). The resulting solution is administered via a clean nasal atomiser or dropper device directed toward the upper nasal mucosa to maximise olfactory nerve contact and CNS uptake. Atomiser delivery produces a more consistent droplet size than dropper delivery and may improve reproducibility in research settings.

For subcutaneous administration, the same aqueous reconstitution is used at an equivalent concentration, administered via insulin syringe into abdominal or lateral thigh subcutaneous tissue. No pH adjustment is required; Selank is stable in solution across the physiological pH range. Subcutaneous use is not the clinically validated delivery route and should be reserved for research contexts where bioavailability consistency outweighs the reduced CNS-targeting advantage of the intranasal route.

Frequently Asked Questions

Is Selank the same as a benzodiazepine? No. Selank produces GABAergic anxiolysis through a mechanism that does not involve the benzodiazepine allosteric site on the GABA-A receptor. It does not produce sedation, cognitive impairment, or physiological dependence at therapeutic doses, which are the principal liabilities of classical benzodiazepines.

Can Selank be combined with Semax? Yes, and this is one of the most thoroughly documented nootropic combinations in Russian peptide research. Semax provides cognitive activation and BDNF upregulation while Selank attenuates stress and anxiety; the two mechanisms are complementary and non-overlapping. No adverse pharmacokinetic interaction has been identified, and they are typically administered at the same time via separate nasal atomisers.

How quickly does anxiolytic effect onset? Most subjects in Russian clinical trials reported measurable anxiety reduction within the first three to five days of daily administration. Acute effects within a single session are subtler than benzodiazepine onset — there is no pronounced sedative signal — which can lead to underestimation of effect on the first dose. The full profile becomes more apparent over the first week.

Does Selank affect memory or cognitive performance? Evidence suggests it does not impair cognition and may modestly enhance it, in contrast to benzodiazepines which reliably impair working memory and attentional performance. The BDNF-upregulating mechanism provides a theoretical basis for mild cognitive benefit, and self-report and open-label data support this, though controlled human cognitive trials are limited.

Is Selank active orally? Oral bioavailability is negligible due to gastric and intestinal protease degradation. Intranasal administration is the validated and preferred route; subcutaneous injection preserves bioavailability but sacrifices the direct olfactory-to-CNS transit pathway.

---

Explore Related Stacks

• Semax + Selank + Pinealon Nootropic Stack
• DSIP + Selank Sleep Stack

Source research-grade Selank

Selank — Tuftsin-Derivative Anxiolytic Heptapeptide is sold for laboratory and in vitro research use only. UK regulatory status: Approved in Russian Federation as a medicinal product (anxiolytic indication). Unapproved in UK, US, EU — laboratory research use only..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk